CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority Review, the company’s New Drug Application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The FDA grants Priority Review to applications fo

Click to view original post